\-\ Texto\\:\\ \ \(0\)\
\-\ patient\\ is\\ a\\ well\\ developed\\,\\ well\\ nourished\\.\\ bilateral\\ optic\\ nerve\\ head\\ edema\\ noted\\.\\ normal\\ visual\\ acuity\\,\\ eomi\\,\\ perrla\\,\\ and\\ all\\ other\\ cranial\\ nerves\\ showed\\ no\\ abnormality\\.\ \(0\)\
\-\ also\\ noted\\ on\\ mri\\ was\\ occipital\\ bone\\ marrow\\ replacement\\ and\\ enhancement\\ on\\ undersurface\\ along\\ with\\ lymphadenopathy\\ on\\ ct\\ making\\ diagnosis\\ of\\ lymphoma\\ likely\\.\\ biopsy\\ of\\ axial\\ lymph\\ nodes\\ and\\ extraconal\\ mass\\ showed\\ presence\\ of\\ b\\ cell\\ sll\\/cll\\ and\\ wbc\\ was\\ 47\\ with\\ differential\\ consistent\\ with\\ this\\ diagnosis\\.\ \(0\)\
\-\ due\\ to\\ slow\\ growth\\ and\\ lack\\ of\\ symptoms\\ at\\ this\\ time\\,\\ the\\ patient\\ may\\ elect\\ to\\ not\\ pursue\\ treatment\\ at\\ this\\ time\\.\\ \\ radiation\\ therapy\\ could\\ be\\ given\\ to\\ orbits\\ to\\ prevent\\ visual\\ problems\\ from\\ continued\\ growth\\ of\\ masses\\.\\ it\\ would\\ be\\ given\\ to\\ the\\ complete\\ orbits\\ at\\ dose\\ of\\ 20\\-25\\ gy\\ in\\ 2\\ gy\\ fractions\\.\\ this\\ will\\ invariably\\ lead\\ to\\ cataracts\\,\\ but\\ retinal\\ damage\\ and\\ xerophthalmia\\ would\\ be\\ unlikely\\ at\\ this\\ dose\\.\\ chemotherapy\\ can\\ also\\ be\\ considered\\ for\\ systemic\\ treatment\\.\ \(0\)\
\-\ mri\\:\\ extraconal\\ mass\\ along\\ the\\ roof\\ of\\ the\\ left\\ orbit\\,\\ 8mm\\ cc\\ x\\ 3\\.8cm\\ ap\\ x\\ 3\\.4cm\\ transverse\\,\\ indistinct\\ from\\ lacrimal\\ gland\\.\\ right\\ lacrimal\\ gland\\ also\\ enlarged\\ or\\ surrounded\\ by\\ mass\\.\ \(0\)\
\-\ b\\-cell\\ lymphoma\ \(1\)\
\-\ metastatic\\ tumors\\ \\(carcinomas\\ of\\ lung\\,\\ prostate\\,\\ gi\\,\\ renal\\,\\ skin\\,\\ \\(breast\\ in\\ female\\)\\)\\;\\ lacrimal\\ gland\\ lesions\\ \\(infiltrative\\ processes\\ and\\ epithelial\\ neoplasms\\)\\;\\ mesenchymal\\ tumors\\ \\(fibroma\\,\\ fibrosarcoma\\,\\ leiomyosarcoma\\,\\ fibrous\\ histiocytoma\\,\\ and\\ rhabdomyosarcoma\\ \\(most\\ common\\ orbit\\ tumor\\ in\\ children\\)\\)\\;\\ neurogenic\\ tumors\\ \\(neurofibroma\\,\\ schwannoma\\,\\ and\\ gliomas\\ and\\ meningiomas\\ of\\ the\\ optic\\ nerve\\)\\;\\ inflammations\\;\\ structural\\ lesions\\ \\(dermoid\\ cysts\\ and\\ mucoceles\\)\\;\\ vascular\\ neoplastic\\ lesions\\;\\ lymphoproliferative\\ lesions\\.\ \(0\)\
\-\ the\\ patient\\ was\\ diagnosed\\ with\\ pseudotumor\\ cerebri\\ 3\\ yrs\\ ago\\ and\\ presented\\ for\\ follow\\ up\\ with\\ opthalmology\\ with\\ no\\ complaints\\ or\\ specific\\ symptoms\\.\\ he\\ did\\ report\\ a\\ 10\\ lb\\ weight\\ loss\\ over\\ past\\ 18\\ mos\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ lacrimal\\:\\ 0\\.05196237634296881\ \(0\)\
\-\ \\;\\:\\ 0\\.04219627475942903\ \(0\)\
\-\ gy\\:\\ 0\\.040890525445899904\ \(0\)\
\-\ extraconal\\:\\ 0\\.03939460622994213\ \(0\)\
\-\ orbits\\:\\ 0\\.03307989217824414\ \(0\)\
\-\ gland\\:\\ 0\\.03249436331600597\ \(0\)\
\-\ tumors\\:\\ 0\\.028658181764915185\ \(0\)\
\-\ lesions\\:\\ 0\\.02723286317076128\ \(0\)\
\-\ dose\\:\\ 0\\.02661733929829056\ \(0\)\
\-\ xerophthalmia\\:\\ 0\\.02623666197609077\ \(0\)\
\-\ orbit\\:\\ 0\\.025622969746724098\ \(0\)\
\-\ sll\\/cll\\:\\ 0\\.02417372393870998\ \(0\)\
\-\ elect\\:\\ 0\\.02417372393870998\ \(0\)\
\-\ 3\\.8cm\\:\\ 0\\.02417372393870998\ \(0\)\
\-\ 3\\.4cm\\:\\ 0\\.02417372393870998\ \(0\)\
\-\ inflammations\\:\\ 0\\.02417372393870998\ \(0\)\
\-\ optic\\:\\ 0\\.023545869164314438\ \(0\)\
\-\ visual\\:\\ 0\\.02305878572236425\ \(0\)\
\-\ opthalmology\\:\\ 0\\.022966982545530916\ \(0\)\
\-\ growth\\:\\ 0\\.022116976167513687\ \(0\)\
\-\ fractions\\:\\ 0\\.02211078590132919\ \(0\)\
\-\ cataracts\\:\\ 0\\.02211078590132919\ \(0\)\
\-\ mucoceles\\:\\ 0\\.021446668189084517\ \(0\)\
\-\ lymphoproliferative\\:\\ 0\\.021446668189084517\ \(0\)\
\-\ invariably\\:\\ 0\\.020904044508150126\ \(0\)\
\-\ pursue\\:\\ 0\\.019383730151703728\ \(0\)\
\-\ 20\\-25\\:\\ 0\\.019383730151703728\ \(0\)\
\-\ undersurface\\:\\ 0\\.019100068902286094\ \(0\)\
\-\ 8mm\\:\\ 0\\.018382324685569162\ \(0\)\
\-\ fibrosarcoma\\:\\ 0\\.018382324685569162\ \(0\)\
\-\ mos\\:\\ 0\\.018382324685569162\ \(0\)\
\-\ nerve\\:\\ 0\\.018327060276710154\ \(0\)\
\-\ would\\:\\ 0\\.01810099332394101\ \(0\)\
\-\ lb\\:\\ 0\\.017804479404494887\ \(0\)\
\-\ given\\:\\ 0\\.017436990431644896\ \(0\)\
\-\ mesenchymal\\:\\ 0\\.017175583292390103\ \(0\)\
\-\ retinal\\:\\ 0\\.017037130864905305\ \(0\)\
\-\ meningiomas\\:\\ 0\\.017037130864905305\ \(0\)\
\-\ along\\:\\ 0\\.016809844505110215\ \(0\)\
\-\ x\\:\\ 0\\.016780156758020696\ \(0\)\
\-\ leiomyosarcoma\\:\\ 0\\.016778168433388547\ \(0\)\
\-\ histiocytoma\\:\\ 0\\.016778168433388547\ \(0\)\
\-\ gliomas\\:\\ 0\\.016778168433388547\ \(0\)\
\-\ cerebri\\:\\ 0\\.016778168433388547\ \(0\)\
\-\ showed\\:\\ 0\\.016677400404307718\ \(0\)\
\-\ indistinct\\:\\ 0\\.016656674402078266\ \(0\)\
\-\ perrla\\:\\ 0\\.016427623684411218\ \(0\)\
\-\ carcinomas\\:\\ 0\\.016319386648188373\ \(0\)\
\-\ structural\\:\\ 0\\.01621494819636912\ \(0\)\
\-\ yrs\\:\\ 0\\.016114050721143875\ \(0\)\
\-\ acuity\\:\\ 0\\.016016461962742118\ \(0\)\
\-\ b\\-cell\\:\\ 0\\.01583038947172624\ \(0\)\
\-\ be\\:\\ 0\\.01568758003980868\ \(0\)\
\-\ eomi\\:\\ 0\\.0156552689359437\ \(0\)\
\-\ neurogenic\\:\\ 0\\.0156552689359437\ \(0\)\
\-\ epithelial\\:\\ 0\\.015489882474173433\ \(0\)\
\-\ roof\\:\\ 0\\.01541051269119081\ \(0\)\
\-\ nourished\\:\\ 0\\.015333204695943011\ \(0\)\
\-\ \\,\\:\\ 0\\.01530800965722756\ \(0\)\
\-\ \\(\\:\\ 0\\.015049202630080426\ \(0\)\
\-\ also\\:\\ 0\\.015041246372054923\ \(0\)\
\-\ \\)\\:\\ 0\\.014865368585693855\ \(0\)\
\-\ pseudotumor\\:\\ 0\\.01471523039600776\ \(0\)\
\-\ infiltrative\\:\\ 0\\.014593736364697475\ \(0\)\
\-\ lymphoma\\:\\ 0\\.014536896633270747\ \(0\)\
\-\ surrounded\\:\\ 0\\.014534799973935036\ \(0\)\
\-\ time\\:\\ 0\\.014366673971662573\ \(0\)\
\-\ rhabdomyosarcoma\\:\\ 0\\.014310075115279841\ \(0\)\
\-\ this\\:\\ 0\\.014302637102888883\ \(0\)\
\-\ fibroma\\:\\ 0\\.01415201015898833\ \(0\)\
\-\ making\\:\\ 0\\.014101133869228507\ \(0\)\
\-\ neurofibroma\\:\\ 0\\.014101133869228507\ \(0\)\
\-\ at\\:\\ 0\\.013782894676567058\ \(0\)\
\-\ slow\\:\\ 0\\.013767451434345452\ \(0\)\
\-\ processes\\:\\ 0\\.013767451434345452\ \(0\)\
\-\ cc\\:\\ 0\\.013635154521932258\ \(0\)\
\-\ damage\\:\\ 0\\.013592330898562913\ \(0\)\
\-\ prostate\\:\\ 0\\.0135084890028287\ \(0\)\
\-\ 47\\:\\ 0\\.013347574653810021\ \(0\)\
\-\ neoplastic\\:\\ 0\\.013014485617488636\ \(0\)\
\-\ neoplasms\\:\\ 0\\.01294526876580927\ \(0\)\
\-\ nerves\\:\\ 0\\.012911254790143724\ \(0\)\
\-\ symptoms\\:\\ 0\\.012676532600584161\ \(0\)\
\-\ prevent\\:\\ 0\\.012621450730544987\ \(0\)\
\-\ replacement\\:\\ 0\\.012414070014360493\ \(0\)\
\-\ lead\\:\\ 0\\.012193510573426795\ \(0\)\
\-\ systemic\\:\\ 0\\.01216705537278023\ \(0\)\
\-\ unlikely\\:\\ 0\\.012114840165485858\ \(0\)\
\-\ noted\\:\\ 0\\.01205607850269401\ \(0\)\
\-\ b\\:\\ 0\\.011988174646382299\ \(0\)\
\-\ occipital\\:\\ 0\\.011866680615072015\ \(0\)\
\-\ problems\\:\\ 0\\.011772934582157219\ \(0\)\
\-\ mri\\:\\ 0\\.011686165803063213\ \(0\)\
\-\ diagnosis\\:\\ 0\\.01167987696893107\ \(0\)\
\-\ schwannoma\\:\\ 0\\.011615665292352518\ \(0\)\
\-\ dermoid\\:\\ 0\\.011593861601602301\ \(0\)\
\-\ lack\\:\\ 0\\.011572216484551468\ \(0\)\
\-\ well\\:\\ 0\\.011506434243861018\ \(0\)\
\-\ nodes\\:\\ 0\\.011487176685610825\ \(0\)\
\-\ gi\\:\\ 0\\.011424954409362868\ \(0\)\
\-\ report\\:\\ 0\\.01138418403924929\ \(0\)\
\-\ marrow\\:\\ 0\\.011188311364935088\ \(0\)\
\-\ cranial\\:\\ 0\\.011058488083756843\ \(0\)\
\-\ complaints\\:\\ 0\\.011040395684719992\ \(0\)\
\-\ 18\\:\\ 0\\.011040395684719992\ \(0\)\
\-\ children\\:\\ 0\\.010986769180247736\ \(0\)\
\-\ continued\\:\\ 0\\.010951547580107846\ \(0\)\
\-\ lymphadenopathy\\:\\ 0\\.010814687124030992\ \(0\)\
\-\ mass\\:\\ 0\\.010611258990603254\ \(0\)\
\-\ specific\\:\\ 0\\.010512841354846755\ \(0\)\
\-\ treatment\\:\\ 0\\.010295339045243374\ \(0\)\
\-\ fibrous\\:\\ 0\\.010280435292431764\ \(0\)\
\-\ lymph\\:\\ 0\\.01026649526471621\ \(0\)\
\-\ considered\\:\\ 0\\.01026649526471621\ \(0\)\
\-\ transverse\\:\\ 0\\.010197758018303563\ \(0\)\
\-\ cysts\\:\\ 0\\.009962673460807639\ \(0\)\
\-\ developed\\:\\ 0\\.009791861562008078\ \(0\)\
\-\ skin\\:\\ 0\\.009768240878687435\ \(0\)\
\-\ ago\\:\\ 0\\.009466454823801335\ \(0\)\
\-\ abnormality\\:\\ 0\\.00938261292806712\ \(0\)\
\-\ could\\:\\ 0\\.00938261292806712\ \(0\)\
\-\ breast\\:\\ 0\\.00938261292806712\ \(0\)\
\-\ diagnosed\\:\\ 0\\.009351771299985136\ \(0\)\
\-\ ap\\:\\ 0\\.009301068362031064\ \(0\)\
\-\ wbc\\:\\ 0\\.009271056102904202\ \(0\)\
\-\ presence\\:\\ 0\\.009231504816836694\ \(0\)\
\-\ did\\:\\ 0\\.009182793574383702\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.009115910074824003\ \(0\)\
\-\ weight\\:\\ 0\\.009115910074824003\ \(0\)\
\-\ biopsy\\:\\ 0\\.009022896552490358\ \(0\)\
\-\ complete\\:\\ 0\\.008950523613053733\ \(0\)\
\-\ was\\:\\ 0\\.008823906448336489\ \(0\)\
\-\ enlarged\\:\\ 0\\.008677443661857161\ \(0\)\
\-\ masses\\:\\ 0\\.008597001184512164\ \(0\)\
\-\ 10\\:\\ 0\\.008573286393889613\ \(0\)\
\-\ radiation\\:\\ 0\\.008345985861792667\ \(0\)\
\-\ vascular\\:\\ 0\\.008338700202153859\ \(0\)\
\-\ follow\\:\\ 0\\.008080950809364386\ \(0\)\
\-\ past\\:\\ 0\\.008080950809364386\ \(0\)\
\-\ differential\\:\\ 0\\.008074285206407529\ \(0\)\
\-\ will\\:\\ 0\\.007956788745176017\ \(0\)\
\-\ patient\\:\\ 0\\.007648142240324892\ \(0\)\
\-\ renal\\:\\ 0\\.007641296278149015\ \(0\)\
\-\ to\\:\\ 0\\.007626216222196183\ \(0\)\
\-\ from\\:\\ 0\\.007538307816394121\ \(0\)\
\-\ loss\\:\\ 0\\.00738233384663226\ \(0\)\
\-\ lung\\:\\ 0\\.0073665450007105535\ \(0\)\
\-\ axial\\:\\ 0\\.007258307964487712\ \(0\)\
\-\ head\\:\\ 0\\.007213099138612785\ \(0\)\
\-\ edema\\:\\ 0\\.00719322467092646\ \(0\)\
\-\ all\\:\\ 0\\.00719322467092646\ \(0\)\
\-\ likely\\:\\ 0\\.007173482041475168\ \(0\)\
\-\ he\\:\\ 0\\.007095795660812558\ \(0\)\
\-\ presented\\:\\ 0\\.006932612008995265\ \(0\)\
\-\ cell\\:\\ 0\\.006869764022563947\ \(0\)\
\-\ up\\:\\ 0\\.006838830806708998\ \(0\)\
\-\ enhancement\\:\\ 0\\.006816930851556655\ \(0\)\
\-\ therapy\\:\\ 0\\.006799526179287538\ \(0\)\
\-\ due\\:\\ 0\\.0067865391456929745\ \(0\)\
\-\ common\\:\\ 0\\.006655557178441658\ \(0\)\
\-\ over\\:\\ 0\\.006475126756368936\ \(0\)\
\-\ on\\:\\ 0\\.006463312610405608\ \(0\)\
\-\ and\\:\\ 0\\.006428893061864944\ \(0\)\
\-\ metastatic\\:\\ 0\\.006402111320285983\ \(0\)\
\-\ bone\\:\\ 0\\.006319746075773422\ \(0\)\
\-\ consistent\\:\\ 0\\.006236006752473819\ \(0\)\
\-\ bilateral\\:\\ 0\\.006172076575340607\ \(0\)\
\-\ or\\:\\ 0\\.005961444934307783\ \(0\)\
\-\ 3\\:\\ 0\\.005955284305674225\ \(0\)\
\-\ tumor\\:\\ 0\\.005929262802413128\ \(0\)\
\-\ most\\:\\ 0\\.005871533159904988\ \(0\)\
\-\ other\\:\\ 0\\.0058620194901858585\ \(0\)\
\-\ can\\:\\ 0\\.005768518906157945\ \(0\)\
\-\ it\\:\\ 0\\.005716810668253025\ \(0\)\
\-\ may\\:\\ 0\\.005578358240768225\ \(0\)\
\-\ 2\\:\\ 0\\.005476501477709958\ \(0\)\
\-\ but\\:\\ 0\\.005424116967361719\ \(0\)\
\-\ female\\:\\ 0\\.005228453188832838\ \(0\)\
\-\ no\\:\\ 0\\.0051216913732369165\ \(0\)\
\-\ for\\:\\ 0\\.004339929456206638\ \(0\)\
\-\ by\\:\\ 0\\.004234734831085937\ \(0\)\
\-\ normal\\:\\ 0\\.003986941829163991\ \(0\)\
\-\ in\\:\\ 0\\.0037624752691094187\ \(0\)\
\-\ not\\:\\ 0\\.003675055570660522\ \(0\)\
\-\ ct\\:\\ 0\\.0035574513493810797\ \(0\)\
\-\ \\:\\:\\ 0\\.00336391314282936\ \(0\)\
\-\ of\\:\\ 0\\.00312063752137469\ \(0\)\
\-\ left\\:\\ 0\\.002845551396645579\ \(0\)\
\-\ right\\:\\ 0\\.0026834277056857637\ \(0\)\
\-\ the\\:\\ 0\\.0024687372268504607\ \(0\)\
\-\ a\\:\\ 0\\.0023607131060631027\ \(0\)\
\-\ with\\:\\ 0\\.0020893602873194596\ \(0\)\
\-\ is\\:\\ 0\\.00167348445947835\ \(0\)\
\-\ \\.\\:\\ 0\\.00158480071863153\ \(0\)\
